Skip to main content

Table 1 Differences in the mortality rate and noradrenaline-free days between the patients in the PMX-HP-treated group and the control group stratified by SOFA score

From: Potential survival benefit and early recovery from organ dysfunction with polymyxin B hemoperfusion: perspectives from a real-world big data analysis and the supporting mechanisms of action

  28-day mortality range (%)
Fatality/the number of patients (n)
Noradrenaline-free days
Median (IQR)
SOFA score range PMX-HP group Control group p-value PMX-HP group Control group p-value
0–6 15.0–15.2
(69/456)
9.1–16.7
(47/407)
NS 25 (21-–6) 25 (20–26) 0.9287
7–9 14.2–16.1
(83/553)
16.2–22.9
(92/463)
0.0410 25 (20–26) 24 (11–26) 0.0003
10–12 14.8–25.3
(95/510)
25.3–30.6
(145/529)
0.0008 24 (15–26) 22(0–6) 0.0005
13–15 28.5–39.3
(116/356)
24.8–35.5
(118/404)
NS 22 (0–25) 21.5 (0–25) 0.9161
16–24 30.6–61.5
(62/158)
34.6–57.1
(96/230)
NS 14 (0–24) 15 (0–4) 0.3491
  1. Twenty-eight-day mortality range represents the minimum and the maximum number. IQR denotes interquartile range and NS not significant